Groupe la Francaise’s Avadel Pharmaceuticals AVDL Stock Holding History

Groupe la Francaise’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-479,291	Closed	-$10.3M	–	458
2025 Q4	$10.3M	Buy	+479,291	New	+$9.31M	0.14%	97

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Groupe la Francaise's AVDL Position: Q1 2026 in Review

Groupe la Francaise sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 479,291 shares — an estimated $10.3M sold.

Groupe la Francaise first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $10.3M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Groupe la Francaise reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Groupe la Francaise sold 479,291 Avadel Pharmaceuticals shares in Q1 2026, an estimated $10.3M.
Groupe la Francaise first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Groupe la Francaise's Avadel Pharmaceuticals position peaked at $10.3M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Groupe la Francaise's 13F filing for Q1 2026, filed 21 May 2026.